We have been unable to find

other population-based published GSK1210151A mouse data on duration with visual disability in glaucoma. Thus, we found that approximately 1 out of 6 glaucoma patients was bilaterally blind at the last visit, while more than 40% were blind in at least 1 eye. Blindness mostly occurred at late ages, and the great majority of bilaterally blind patients were older than 80 years when the best eye became blind. Life expectancy has increased considerably during the last 50 years, by 10 years in the United States, and is expected to increase further. With longer life expectancy, glaucoma patients will have the disease for a longer time and it is possible that the lifetime risk of glaucoma blindness may increase even further. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Heijl is a consultant to Carl Zeiss Meditec, Allergan, and Alcon; receives lecture fees and payment for development of educational presentations from Allergan; and receives patent royalties from Carl Zeiss Meditec. Dr Bengtsson is a consultant to Carl Zeiss Meditec. This study was supported by the Swedish Research Council (grant K2011-63X-10426-19-3), the Herman

Järnhardt Foundation, the Foundation for Visually Impaired in Former Malmöhus County, and Crown Princess Margareta’s Foundation. Contribution of authors: design of the study (A.H., B.B., D.P.); conduct of the study (A.H., B.B., D.P.); collection of data (D.P.); analysis and interpretation of the data (A.H., B.B., D.P.); preparation of the data (B.B., NVP-AUY922 mouse D.P.); and review and approval of the manuscript (A.H., D.P., B.B.). “
“Giani A, Cigada M, Choudhry N, Deiro AP, Oldani M, Pellegrini

M, Invernizzi A, Duca P, Miller JW, Staurenghi G. Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments. Am J Ophthalmol 2010;150(6):815–824. In the December 2010 issue, two errors occur in Figure 5: 1 In the first part of the figure (Whole Sample), row 4, column 5, the value was incorrectly stated with a minus sign as Spectralis = Stratus x1−83. The correct value should be Spectralis = Stratus PAK6 x1+83 (with a plus sign). The authors regret these errors. “
“Macular edema is the leading cause of decreased visual acuity in patients with diabetic retinopathy.1 and 2 Laser photocoagulation has been the standard-of-care treatment for diabetic macular edema (DME) for decades, based on the Early Treatment Diabetic Retinopathy Study (ETDRS) and other more recent clinical trials.3, 4, 5 and 6 However, because visual acuity improvement post laser is observed infrequently, and because of the frequent recurrence or persistence of DME after laser treatment, there is a need for better treatments for the management of DME (especially for diffuse DME involving the foveal center, since focal DME not involving the foveal center may have a good prognosis after focal laser treatment).